LSD / psilocybin / psilocin and MDMA
https://dxm-atlas.org/en/compare/lsd-vs-mdma/
Two separate pairs are shown: DXM + A and DXM + B. Assessing DXM + A + B falls outside the scope of this comparison.
Comparison sections
Overlapping ranges: the ordering by hazard level remains uncertain
PHI and scope
Conditions and group scope
A
B
Mechanisms
A
B
What could go wrong?
A
B
How well is this understood?
A
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodB
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodMeasurements of drug concentration or metabolism.
Under which conditions was it studied?
A
B
Main limitations
This field lists specific limitations of the evidence described for each entry. “—” means no separate text is shown here; qualifications in the entry’s explanation still apply.
A
B
Sources
Similarities and differences
Effects involved
Only A: 5HT-R — Serotonin receptors
Only B: REL — Monoamine release · 2D6 — CYP2D6 metabolism · SYM — Cardiovascular and thermal stress
Mechanism groups
Shared: Serotonin-related
Only B: Cardiovascular and thermal · Metabolism
Study conditions
Only B: Measurements of how people process a substance
No shared tags are marked in the review.
Conclusion
With psychological effects given relatively little weight, LSD and psilocybin rank below MDMA and MAOIs. These groups differ in the serotonin-elevating mechanisms underlying the assessment [8].
Limitations
A controlled study involved 15 healthy men. They took MDMA by mouth, followed by DXM as a metabolic probe. DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3].
The abstract reports CYP2D6 recovery after approximately 10 days and a recovery half-life of 46.6 hours. The full text estimates that half-life by fitting a monoexponential model to a urinary metabolic-ratio marker. At the 10-day observation, the Results and Discussion describe a remaining departure of the marker from baseline and limitations of the recovery models [3].
These findings describe pharmacokinetics and enzyme-probe measurements. The fold change can differ at other doses because of metabolic saturation and exposure-dependent inhibition. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval.
The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].